William Henry Gmeiner, Ph.D., Professor Cancer Biology

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Comprehensive Cancer Center
Brain Tumor Center of Excellence
Physiology & Pharmacology

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Education & Training

B.A., University of Chicago , 1982
Ph.D., University of Utah , 1989
M.B.A., Wake Forest University , 2007
Fellowship, University Alberta Medical School-Canada, 1991

Memberships

Am Assn Of Cancer Research
Am Chemical Society
Am Soc Of Pharm & Exper Therap

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology Comprehensive Cancer Center
Brain Tumor Center of Excellence
Physiology & Pharmacology

Research Interests

biotechnology, cancer/oncogenesis, drugs/therapeutic agents pharm, molecular biology/molecular me

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Recent Publications

Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol. 2013;41(2):180-188.

Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013;41(8):4650-4659.

Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012;119(15):3561-3570.

Gmeiner WH. Carbon nanotubes for cancer therapy In: Kumar CSSR, ed. Carbon nanomaterials. Weinheim (Germany): Wiley-VCH;2011: 309-332.

Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH. Zn2+ selectively stabilizes FdU-substituted DNA through a unique major groove binding motif. Nucleic Acids Res. 2011;39(10):4490-4498.

Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA. The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs. J Nucleic Acids. 2011;2011():631372.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Blood. 2011;118(21):1109-1110.

Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther. 2010;9(12):3105-3114.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Blood. 2010;116(21):1353.

Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R Jr, Olson J, Guthold M, Gmeiner WH. Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. ACS Nano. 2009;3(9):2667-2673.

Gmeiner WH, Hellmann GM, Shen P. Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Oncol Rep. 2008;19(1):245-251.

Gmeiner WH, Garg S, Hatcher HC, Smith TL, Bourland JD, Garg PK. MicroPET imaging to monitor tumor response to single agent and combined ionizing radiation therapy and FdUMP treatment [abstract]. J Nucl Med. 2007;48(6 Suppl 2):83P.

Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep. 2007;18(1):287-291.

Gmeiner WH. Genetic determinants for activated fluoropyrimidine chemotherapy. Drug Dev Res. 2006;67(2):119-129.